Feed / DYN

Dyne Therapeutics, Inc.

DYN

Healthcare · 26.10 +0.5% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Dyne Therapeutics, Inc.'s move is being confirmed by its market group.

DYN accounts for 5.1% of the group's measured movement across 8.4 effective names. raw member direction is mixed; 8 of 12 session-normalized paths align to the upside. Capital-flow agreement is 17%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveAligned contributor#8 of 12 by movement share
Group movement share5.1%Absolute path energy—not portfolio weight
Relative path+0.69%aligned
Effective breadth8.4 / 12broad
Relative alignment8/12upside path · 4 counter-moving
Capital-flow agreement17%not yet clean
SEQUENCE READ

MIRM, BLTE, ARQT moved materially before DYN. DYN crossed its material path threshold at 15:35 ET.

EVIDENCE COVERAGE

14 of 18 members in Biotech Rare Diseases are active. 0 of 3 disclosed connections are confirming.

What would change this read
  • At least 12 of 18 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as ROIV begins moving with the group.

Invalidation: The live read weakens if participation falls to 6 of 18 members or fewer.

Watch this read

Who this business touches

The relationships behind DYN

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

HTGCHercules Capital, Inc.lenderMay 11, 2026

To date, we have principally raised capital through sales of equity securities and our borrowing under our Loan and Security Agreement, or the Loan Agreement, with Hercules Capital, Inc., or Hercules.

ALNYAlnylam Pharmaceuticals, Inc.competitorMay 11, 2026

We also expect to compete more generally with other companies developing alternative scientific and technological approaches to the treatment of muscle diseases, including other companies working to develop conjugates with oligonucleotides for extra-hepatic d…

Depended on by

BMRNBioMarin Pharmaceutical Inc.competitorFeb 26, 2026

In addition, BMN 351 could have potential competition from clinical product candidates for exon 51 skipping amenable DMD by Dyne Therapeutics, Inc.

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

DYN is currently a Participant in the organic co-movement group Biotech Rare Diseases. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.